Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 52-Week High – Time to Buy?

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) shares reached a new 52-week high during trading on Tuesday . The company traded as high as $42.30 and last traded at $42.04, with a volume of 127574 shares traded. The stock had previously closed at $41.40.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Weiss Ratings reissued a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Wednesday, October 8th. Wall Street Zen cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 2nd. Zacks Research lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. The Goldman Sachs Group upped their price target on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Finally, Citigroup lifted their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, Kiniksa Pharmaceuticals International currently has a consensus rating of “Moderate Buy” and a consensus target price of $52.00.

Kiniksa Pharmaceuticals International Stock Up 0.5%

The firm has a market cap of $3.15 billion, a price-to-earnings ratio of 92.26 and a beta of 0.16. The company’s fifty day moving average is $38.04 and its 200 day moving average is $32.54.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, October 28th. The company reported $0.23 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.08). The company had revenue of $180.86 million during the quarter, compared to analyst estimates of $166.64 million. Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The company’s quarterly revenue was up 61.2% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.18) EPS. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Mark Ragosa sold 19,900 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $40.94, for a total value of $814,706.00. Following the transaction, the chief financial officer directly owned 31,086 shares of the company’s stock, valued at $1,272,660.84. This trade represents a 39.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Sanj K. Patel sold 97,390 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Wednesday, October 22nd. The shares were sold at an average price of $38.83, for a total value of $3,781,653.70. Following the completion of the transaction, the chief executive officer owned 111,794 shares in the company, valued at approximately $4,340,961.02. This represents a 46.56% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 610,043 shares of company stock valued at $23,093,378 in the last 90 days. 53.48% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in KNSA. Nuveen LLC acquired a new position in shares of Kiniksa Pharmaceuticals International in the 1st quarter valued at about $16,992,000. Arrowstreet Capital Limited Partnership acquired a new position in shares of Kiniksa Pharmaceuticals International during the 2nd quarter valued at $20,349,000. Qube Research & Technologies Ltd increased its stake in Kiniksa Pharmaceuticals International by 277.8% in the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after purchasing an additional 653,236 shares in the last quarter. Acadian Asset Management LLC raised its holdings in shares of Kiniksa Pharmaceuticals International by 170.3% during the first quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company’s stock valued at $22,961,000 after purchasing an additional 651,700 shares during the period. Finally, Rubric Capital Management LP boosted its position in shares of Kiniksa Pharmaceuticals International by 15.6% during the 2nd quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock worth $108,184,000 after purchasing an additional 526,567 shares in the last quarter. Institutional investors own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.